12-Week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

This study is currently recruiting participants.

Verified by Daiichi Sankyo Inc., March 2009

First Received: February 4, 2008 Last Updated: March 10, 2009 History of Changes

Sponsored by:	Daiichi Sankyo Inc.
Information provided by:	Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:	NCT00616733

Purpose

This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.

Condition	Intervention	Phase
Multiple Sclerosis	Drug: CS-0777 tablets	Phase I

MedlinePlus related topics: Multiple Sclerosis

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment
Official Title:	An Open-Label, Escalating-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis

Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:

Safety and tolerability. [ Time Frame: 12 weeks, with 4 weeks to follow-up ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Pharmacodynamic response (lymphocyte counts Pharmacokinetics Exploratory efficacy based on brain MRI lesions) [ Time Frame: 12 weeks, with 4 weeks to follow up. ] [ Designated as safety issue: No ]

Estimated Enrollment:	18
Study Start Date:	March 2008
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: CS-0777 tablets 0.1 mg, once-weekly, for 12 weeks
2: Experimental	Drug: CS-0777 tablets 0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
3: Experimental	Drug: CS-0777 tablets 0.6 mg, once-weekly or once every 2 weeks, for 12 weeks

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of clinically isolated syndrome or a relapsing form(s) of MS, based on Poser or McDonald criteria (may include patients with secondary progressive disease)
Clinical relapse within the past 3 years or a gadolinium enhancing lesion on a brain MRI scan within the past 12 months
Baseline EDSS score of 0 - 6.5
Female subjects who are sexually active, unless sterile or post-menopausal for at least 1 year, must be willing to use double-barrier contraception

Exclusion Criteria:

Primary progressive MS
Any medical condition that predisposes to immunocompromise
History of malignancy, tuberculosis, invasive fungal infections, herpes zoster infection (or shingles), or other opportunistic infection, or any current active infection
Concurrent diagnosis of any other autoimmune disease (eg, rheumatoid arthritis or lupus)
Treatment with cyclophosphamide or mitoxantrone within 6 months of study initiation
Treatment with cyclosporine, azathioprine, methotrexate or other immunosuppressant within 3 months of study initiation
Treatment with interferon beta or glatiramer acetate within 2 months of study initiation
Prior treatment with natalizumab or rituximab

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00616733

Contacts

Contact: Sharon Herbert, PhD

S.Herbert@Medpace.com

Locations

United States, Colorado
	Recruiting
Denver, Colorado, United States
United States, Florida
	Recruiting
Port Orange, Florida, United States
United States, Kansas
	Recruiting
Lenexa, Kansas, United States
United States, Montana
	Recruiting
Billings, Montana, United States
United States, Pennsylvania
	Recruiting
Philadelphia, Pennsylvania, United States

Sponsors and Collaborators

Daiichi Sankyo Inc.

More Information

No publications provided

Responsible Party:	Daiichi Sankyo, Inc. ( James Moberly, PhD, Senior Director, Clinical Development )
Study ID Numbers:	CS0777-A-U102, IND 77,409
Study First Received:	February 4, 2008
Last Updated:	March 10, 2009
ClinicalTrials.gov Identifier:	NCT00616733 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Daiichi Sankyo Inc.:

Multiple sclerosis, relapsing, secondary progressive, clinically isolated syndrome, MRI

Study placed in the following topic categories:

Autoimmune Diseases
Multiple Sclerosis
Demyelinating Diseases
Neoplasm Metastasis

Demyelinating Autoimmune Diseases, CNS
Sclerosis
Autoimmune Diseases of the Nervous System

Additional relevant MeSH terms:

Pathologic Processes
Autoimmune Diseases
Multiple Sclerosis
Immune System Diseases
Demyelinating Diseases

Nervous System Diseases
Demyelinating Autoimmune Diseases, CNS
Sclerosis
Autoimmune Diseases of the Nervous System

ClinicalTrials.gov processed this record on May 07, 2009